Incidence of new-onset hypertension in cancer patients: A retrospective cohort study

International Journal of Hypertension

Volumn 2013, Issue , 2013, Pages

  Fraeman, Kathy H ^a   Nordstrom, Beth L ^a   Luo, Weixiu ^a   Landis, Sarah H ^b   Shantakumar, Sumitra ^c  

^a EVIDERA   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84893845037     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.1155/2013/379252     Document Type: Article

References (21)

1. Cutler J. A., Sorlie P. D., Wolz M., Thom T., Fields L. E., Roccella E. J., Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008 52 5 818 827 2-s2.0-55949126144 10.1161/HYPERTENSIONAHA.108.113357
2. Fields L. E., Burt V. L., Cutler J. A., Hughes J., Roccella E. J., Sorlie P., The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension 2004 44 4 398 404 2-s2.0-4644242120 10.1161/01.HYP.0000142248.54761.56 (Pubitemid 39281486)
3. Yancik R., Wesley M. N., Ries L. A., Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer 1998 82 11 2123 2134 (Pubitemid 28240818)
4. Yancik R., Wesley M. N., Ries L. A. G., Havlik R. J., Edwards B. K., Yates J. W., Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. The Journal of the American Medical Association 2001 285 7 885 892 2-s2.0-0035925169 (Pubitemid 32171549)
5. Janssen-Heijnen M. L. G., Schipper R. M., Razenberg P. P. A., Crommelin M. A., Coebergh J.-W. W., Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer 1998 21 2 105 113 2-s2.0-0032432786 10.1016/S0169-5002(98)00039-7 (Pubitemid 29028028)
6. Janssen-Heijnen M. L. G., Smulders S., Lemmens V. E. P. P., Smeenk F. W. J. M., van Geffen H. J. A. A., Coebergh J. W. W., Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax 2004 59 7 602 607 2-s2.0-3142622929 10.1136/thx.2003.018044 (Pubitemid 38901520)
7. López-Encuentra A., Comorbidity in operable lung cancer: a multicenter descriptive study on 2992 patients. Lung Cancer 2002 35 3 263 269 2-s2.0-0036175605 10.1016/S0169-5002(01)00422-6 (Pubitemid 34158659)
8. Smith A. W., Reeve B. B., Bellizzi K. M., Harlan L. C., Klabunde C. N., Amsellem M., Bierman A. S., Hays R. D., Cancer, comorbidities, and health-related quality of life of older adults. Health Care Financing Review 2008 29 4 41 56 2-s2.0-50249165345
9. Ko C., Chaudhry S., The need for a multidisciplinary approach to cancer care. Journal of Surgical Research 2002 105 1 53 57 2-s2.0-0036297669 10.1006/jsre.2002.6449 (Pubitemid 34713212)
10. Havlik R. J., Yancik R., Long S., Ries L., Edwards B., The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer 1994 74 7, supplement 2101 2106 2-s2.0-0028021894 (Pubitemid 24304381)
11. Tammemagi C. M., Nerenz D., Neslund-Dudas C., Feldkamp C., Nathanson D., Comorbidity and survival disparities among black and white patients with breast cancer. The Journal of the American Medical Association 2005 294 14 1765 1772 2-s2.0-26444519200 10.1001/jama.294.14.1765 (Pubitemid 41434622)
12. Piccirillo J. F., Tierney R. M., Costas I., Grove L., Spitznagel E. L. Jr., Prognostic importance of comorbidity in a hospital-based cancer registry. The Journal of the American Medical Association 2004 291 20 2441 2447 2-s2.0-2442696436 10.1001/jama.291.20.2441 (Pubitemid 38669187)
13. Satariano W. A., Ragland D. R., The effect of comorbidity on 3-year survival of women with primary breast cancer. Annals of Internal Medicine 1994 120 2 104 110 2-s2.0-0028156819 (Pubitemid 24027550)
14. Yeh E. T. H., Cardiotoxicity induced by chemotherapy and antibody therapy. Annual Review of Medicine 2006 57 485 498 2-s2.0-32944475309 10.1146/annurev.med.57.121304.131240 (Pubitemid 43262003)
15. Townsend R. R., Mohler E. R., Townsend R. R., Hypertension and cancer chemotherapies. Advanced Therapy in Hypertension and Vascular Disease 2006 Toronto, Canada BC Decker 502 507
16. Jain M., Townsend R. R., Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Current Hypertension Reports 2007 9 4 320 328 2-s2.0-34548480949 10.1007/s11906-007-0058-7 (Pubitemid 47377031)
17. Daher I. N., Yeh E. T., Vascular complications of selected cancer therapies. Nature Clinical Practice Cardiovascular Medicine 2008 5 12 797 805
18. Ranpura V., Pulipati B., Chu D., Zhu X., Wu S., Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. American Journal of Hypertension 2010 23 5 460 468 2-s2.0-77951100677 10.1038/ajh.2010.25
19. Cao Y., Tan A., Gao F., Liu L., Liao C., Mo Z., A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. International Journal of Colorectal Disease 2009 24 6 677 685 2-s2.0-67349286163 10.1007/s00384-009-0655- 9
20. Izzedine H., Ederhy S., Goldwasser F., Soria J. C., Milano G., Cohen A., Khayat D., Spano J. P., Management of hypertension in angiogenesis inhibitor-treated patients. Annals of Oncology 2009 20 5 807 815 2-s2.0-65549122619 10.1093/annonc/mdn713
21. Chobanian A. V., Bakris G. L., Black H. R., Cushman W. C., Green L. A., Izzo J. L. Jr., Jones D. W., Materson B. J., Oparil S., Wright J. T. Jr., Roccella E. J., Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 42 6 1206 1252 2-s2.0-0347423198 10.1161/01.HYP.0000107251.49515.c2 (Pubitemid 37553153)